摘要
目的探讨胸腺肽致过敏性休克的规律和特点,为临床安全用药提供参考。方法检索1979年至2008年国内医药学期刊公开报道的相关病例并统计分析。结果共检索到胸腺肽致过敏性休克病例52例,男30例,女22例;过敏性休克多发生在给药2～5min内,无死亡病例,预后良好。结论胸腺肽引起过敏性休克的发生机制涉及患者体质等多方面因素,应引起临床高度重视。
Objective To investigate the patterns and features of anaphylactic shock induced by thymosin, and to provide the reference for the clinical drug use. Methods The adverse drug reaction （ADR） reports about anaphylactic shock induced by thymosin, published in Chinese medical journals during the period 1979- 2008, were retrieved and analyzed. Results 52 cases of anaphylactic shock induced by thymosin were reported from 1979 to 2008, of which 30 cases were male and 22 females. Anaphylactic shock was found to occur most within 2- 5 min after medication. There were eusemia and no death in 52 cases. Conclusion Thymosin may cause anaphylactic shock, and its mechanism includes many factors, such as patient＇s physical constitution, which should be closely watched.
出处
《中国药业》
CAS
2009年第13期38-39,共2页
China Pharmaceuticals
关键词
胸腺肽
过敏性休克
安全用药
thymosin
anaphylactic shock
safe drug use
